Drug Profile


Alternative Names: MK-0594; VPD-737

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Epidermolysis Bullosa Research Partnership; Menlo Therapeutics; Merck & Co; Stanford University; Velocity Pharmaceutical Development
  • Class Antipruritics; Cyclopentanes; Isoindoles; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cough; Prurigo nodularis; Pruritus
  • Discontinued Alcoholism; Overactive bladder

Most Recent Events

  • 26 Oct 2017 Phase-II clinical trials in Cough in United Kingdom (PO) (NCT03282591), USA (PO) (NCT03282591)
  • 17 Oct 2017 Menlo plans a phase III trial for Prurigo nodularis in the first half of 2018
  • 22 Sep 2017 Menlo Therapeutics plans a phase II trial for Cough (NCT03282591)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top